OneAscent Family Office LLC Buys 3,871 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

OneAscent Family Office LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 75.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,984 shares of the biopharmaceutical company's stock after acquiring an additional 3,871 shares during the period. Gilead Sciences accounts for 0.9% of OneAscent Family Office LLC's portfolio, making the stock its 22nd largest holding. OneAscent Family Office LLC's holdings in Gilead Sciences were worth $1,006,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Bridgewater Associates LP boosted its holdings in Gilead Sciences by 122.7% during the fourth quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock worth $42,577,000 after purchasing an additional 253,994 shares during the last quarter. Nissay Asset Management Corp Japan ADV boosted its position in Gilead Sciences by 5.2% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock worth $26,750,000 after purchasing an additional 14,009 shares during the period. Golden State Wealth Management LLC raised its position in shares of Gilead Sciences by 14.5% in the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock valued at $97,000 after purchasing an additional 109 shares during the period. Ontario Teachers Pension Plan Board lifted its position in Gilead Sciences by 54.6% during the fourth quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock worth $3,422,000 after acquiring an additional 13,086 shares during the last quarter. Finally, Mufg Securities Americas Inc. bought a new stake in Gilead Sciences in the 4th quarter valued at $1,699,000. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the sale, the insider owned 121,152 shares of the company's stock, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the transaction, the chief executive officer directly owned 615,725 shares of the company's stock, valued at $68,006,826.25. The trade was a 1.60% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 72,000 shares of company stock worth $7,844,775 over the last ninety days. Company insiders own 0.27% of the company's stock.

Gilead Sciences Stock Down 0.5%

GILD traded down $0.58 during mid-day trading on Friday, reaching $108.22. 6,627,889 shares of the stock were exchanged, compared to its average volume of 7,673,118. The company has a 50 day moving average price of $108.81 and a two-hundred day moving average price of $105.26. The stock has a market capitalization of $134.62 billion, a PE ratio of 22.78, a price-to-earnings-growth ratio of 0.70 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences, Inc. has a 1 year low of $70.78 and a 1 year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm's revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.32) earnings per share. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.92%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Analysts Set New Price Targets

A number of research firms recently commented on GILD. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Oppenheimer decreased their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Cantor Fitzgerald began coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective for the company. Morgan Stanley lifted their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Finally, JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Nine research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $111.38.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.